Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Medicinova Inc
(NQ:
MNOV
)
1.970
-0.030 (-1.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,297
Open
1.990
Bid (Size)
1.900 (1)
Ask (Size)
2.190 (3)
Prev. Close
2.000
Today's Range
1.970 - 1.990
52wk Range
1.120 - 2.160
Shares Outstanding
49,046,246
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
September 30, 2024
Academic group to receive a total of $22 million for the trial
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
September 09, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Performance
YTD
+19.39%
+19.39%
1 Month
+19.39%
+19.39%
3 Month
+40.71%
+40.71%
6 Month
+29.61%
+29.61%
1 Year
-1.99%
-1.99%
More News
Read More
MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
September 03, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 03, 2024
Via
Benzinga
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
August 29, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MNOV Stock Earnings: MediciNova Beats EPS for Q2 2024
August 19, 2024
Via
InvestorPlace
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
June 20, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
June 05, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
June 03, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
May 28, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
May 20, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
May 14, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024
May 10, 2024
Via
InvestorPlace
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
May 07, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
April 05, 2024
Via
Benzinga
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
April 02, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 27, 2024
Via
Benzinga
Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket
March 27, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 27, 2024
Via
InvestorPlace
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
March 26, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
March 20, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
March 12, 2024
From
MediciNova, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 16, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 13, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
